Navigation Links
Environment, Energy and Ethics conference at UD, Sept. 21-23
Date:9/13/2007

Distinguished speakers from across the United States and abroad will present at Environment, Energy, and Ethics: Science and Responsibility for the 21st Century, an interdisciplinary conference set for Friday-Sunday, Sept. 21-23, at the University of Delaware's Clayton Hall Conference Center in Newark, Del.

Global climate change and sustainable business, the ethical basis of carbon trading, responsible faith communities and environmental role modeling, community-supported agriculture, and a universal right to water are among the many topics that will be highlighted during sessions on private-sector responsibility, markets, international law, environmental policy, religion and culture, and technology.

Keynote addresses will be delivered by Holmes Rolston III, University Distinguished Professor of Philosophy at Colorado State University, who is internationally regarded as a leading environmental ethicist, and David McCurdy, executive vice president of Enviance Inc., an innovative corporate provider of information management services relating to greenhouse gas, environmental, health and safety compliance.

Solutions to environmental problems require many forms of expertise, and the scholars at this conference will contribute to that crucial interdisciplinary dialogue, said Tom Powers, who leads the University's Science, Ethics and Public Policy Program. Powers and colleague Mark Greene, both assistant professors of philosophy at UD, are the conference organizers.

McCurdy's talk, The World Needs a Ruler: Life with Carbon on the Balance Sheet, will be presented during the opening reception at 7 p.m., Friday, Sept. 21. He will provide an overview of recent decisions in the scientific, financial and legal communities that have affected greenhouse gas management.

McCurdy oversees worldwide sales and account management at Enviance Inc. Founded in 1999 and based in Carlsbad, Calif., the company provides Internet-based services
'/>"/>

Contact: Tracey Bryant
tbryant@udel.edu
302-831-8185
University of Delaware
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Smoking Ban Improves Dublin Environment, Health: Study
2. For better mood and energy!! Work-up in short span
3. Radiofrequency Energy Cooks Tumors Without Surgery
4. Energy intake directly related to portion size
5. Should we avoid energy drinks to protect our teeth?
6. Energy Therapy For Quicker Healing
7. Pollution Free Hydrogen based fuel for Energy
8. Burning energy and its impact on health during exercise can be of genetic origin
9. Obesity Can Be Caused By Consumption Of Energy Drinks
10. Bird Flu Likely To Reduce World Energy Demand
11. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 1FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 2FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 3FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 4VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 1VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 3Americans Spend Billions on Alternative Medicine 53255 1Americans Spend Billions on Alternative Medicine 53255 2Americans Spend Billions on Alternative Medicine 53255 3
Other Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5